Yangsong Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yangsong Xu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Changyang Gong
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
3 shared publications - Hao Le
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University
2 shared publications Qinjie Wu
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
2 shared publicationsYingjie Li
2 shared publicationsChao Liu
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
1 shared publicationDongxue Huang
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
1 shared publication
Latest Publications
- Open Access
- 1 August 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 62, 263-281
Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer
Chronic inflammation in intermediate/advanced tumors drives burdensome protumor immune cell communication, thereby weakening immunotherapy. Conventional anti-inflammatory therapies focus on alleviating chronic inflammation whereas ignore dysfunction and scarcity of myeloid and T cells, which hinder their intercellular communication restoration. To address the dilemma, an inflammatory condition-triggered protumor inflammation-immunosurveillance shift hydrogel (TRANS) is developed to initiate adaptive immune responses mediated by intercellular communication. Triggered by inflammatory conditions, TRANS releases celecoxib (CXB) to inhibit the COX-2/PGE2 pathway, thereby reprogramming tumor-associated macrophages and mitigating protumor inflammation. Furthermore, TRANS incorporates FMS-like tyrosine kinase 3 ligands (Flt-3L) and 4-1BB agonists (α-CD137) to respectively recruit type 1 conventional DC (cDC1) and revitalize tumor-infiltrating T cells, to rejuvenate immunosurveillance. TRANS inhibits 87.50% and 88.74% of primary and secondary colorectal tumors, generates antitumor immune memory to resist tumor rechallenge, and significantly reduces lung and liver metastases. Rechallenge model shows TRANS leads to antitumor immune memory formation. Single-cell RNA sequencing is preform to elucidate the mechanism of TRANS, which exhibits that TRANS exerts antitumor effects by optimizing the crosstalk between myeloid cells and T cells via CXCL9/10-CXCR3/DPP4. TRANS further gains better control of colorectal cancer when combined with immune checkpoints inhibitors. This study offers a novel perspective on immunotherapy by rebalancing inflammation-immunity dynamics.
- 1 August 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 62, 263-281
Open AccessChronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer
Chronic inflammation in intermediate/advanced tumors drives burdensome protumor immune cell communication, thereby weakening immunotherapy. Conventional anti-inflammatory therapies focus on alleviating chronic inflammation whereas ignore dysfunction and scarcity of myeloid and T cells, which hinder their intercellular communication restoration. To address the dilemma, an inflammatory condition-triggered protumor inflammation-immunosurveillance shift hydrogel (TRANS) is developed to initiate adaptive immune responses mediated by intercellular communication. Triggered by inflammatory conditions, TRANS releases celecoxib (CXB) to inhibit the COX-2/PGE2 pathway, thereby reprogramming tumor-associated macrophages and mitigating protumor inflammation. Furthermore, TRANS incorporates FMS-like tyrosine kinase 3 ligands (Flt-3L) and 4-1BB agonists (α-CD137) to respectively recruit type 1 conventional DC (cDC1) and revitalize tumor-infiltrating T cells, to rejuvenate immunosurveillance. TRANS inhibits 87.50% and 88.74% of primary and secondary colorectal tumors, generates antitumor immune memory to resist tumor rechallenge, and significantly reduces lung and liver metastases. Rechallenge model shows TRANS leads to antitumor immune memory formation. Single-cell RNA sequencing is preform to elucidate the mechanism of TRANS, which exhibits that TRANS exerts antitumor effects by optimizing the crosstalk between myeloid cells and T cells via CXCL9/10-CXCR3/DPP4. TRANS further gains better control of colorectal cancer when combined with immune checkpoints inhibitors. This study offers a novel perspective on immunotherapy by rebalancing inflammation-immunity dynamics.
- Open Access
- 9 September 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (11) , 5933-5944
A self-cascade nanoCRISPR prompts transcellular penetration to potentiate gene editing and tumor killing
- 9 September 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (11) , 5933-5944
Open AccessA self-cascade nanoCRISPR prompts transcellular penetration to potentiate gene editing and tumor killing
- Open Access
- 17 May 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (6) , 2818-2844
Advancements in CRISPR/Cas systems for disease treatment
- 17 May 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (6) , 2818-2844
Open AccessAdvancements in CRISPR/Cas systems for disease treatment